Cuban-China Joint Venture Plans Clinical Trials and Cancer Drug Production in China
Cuba-China joint venture plans clinical trials for Itolizumab and tech transfer for cancer treatments.
Yanet Borrego, deputy general director and representative of BPL's vice-presidency in Cuba, said that the joint venture Biotech Pharmaceuticals Limited (BPL) is preparing clinical trials in China for the monoclonal antibody Itolizumab, which is registered in Cuba and used to treat autoimmune illnesses.
According to a report
in Prensa Latina, she continued, these studies would concentrate on
graft-versus-host disease and dermatomyositis.
The BPL representative noted that the joint venture is
anticipated to be prepared to begin production and clinical trials of this
medication in China between 2025 and 2026. They are currently in the process of
transferring the technology associated with the production process of Cimavax,
the Cuban vaccine against lung cancer.She said that nimotuzumab, a medication
for head and neck cancer, was just authorised in the Asian Giant.
Elizabeth Arias Valdés, general manager of Cimab, S.A., the
business that owns BPL, told Granma that this product is the firm's top seller,
selling over 100 million copies a year, and is regarded as one of the key
offerings of Cuban biotechnology.
According to Borrego, the firm is also developing nine
cutting-edge items in partnership with the Cuban side. These products are now
in the research and development stage and should be available for purchase in
ten years or less.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Discussion